In conclusion, our study unveiled the pivotal role of the cross-talk between YY1 and PEBP1 in tumor progression, encompassing genetic alterations, tumor immunity, and the tumor microenvironment, while also highlighting their potential influence on anticancer drug sensitivity, offering fresh insights and therapeutic targets for cancer treatment. This evidence concerns the gene YY1 and neoplasm.